| A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects |
56 |
| Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies |
28 |
| Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review |
27 |
| Current and Emerging Treatment Strategies for Neuronal Ceroid Lipofuscinoses |
20 |
| Current Approaches and New Developments in the Pharmacological Management of Tourette Syndrome |
18 |
| Convergent Mechanisms Underlying Rapid Antidepressant Action |
18 |
| Pathophysiological Mechanisms in Migraine and the Identification of New Therapeutic Targets |
17 |
| Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010 |
16 |
| Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy |
14 |
| Cancer Risk in Patients with Multiple Sclerosis: Potential Impact of Disease-Modifying Drugs |
14 |
| Depression in Multiple Sclerosis: Epidemiology, Aetiology, Diagnosis and Treatment |
14 |
| Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US |
14 |
| A Systematic Review and Meta-Analysis of the Risk of Dementia Associated with Benzodiazepine Use, After Controlling for Protopathic Bias |
13 |
| Prescribed Dose of Opioids and Overdose: A Systematic Review and Meta-Analysis of Unintentional Prescription Opioid Overdose |
13 |
| Efficacy and Safety of Adjunctive Cannabidiol in Patients with Lennox-Gastaut Syndrome: A Systematic Review and Meta-Analysis |
12 |
| Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis |
12 |
| Venous Thromboembolism During Treatment with Antipsychotics: A Review of Current Evidence |
12 |
| A Close Look at BACE1 Inhibitors for Alzheimer's Disease Treatment |
11 |
| Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer's and Parkinson's Diseases |
11 |
| Intravenous Brivaracetam in the Treatment of Status Epilepticus: A Systematic Review |
11 |
| Ketamine for Refractory Status Epilepticus: A Systematic Review |
10 |
| Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study |
10 |
| Alzheimer's Disease Clinical Trials: Moving Toward Successful Prevention |
10 |
| Mixed States: Modelling and Management |
10 |
| Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations |
10 |
| Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis |
10 |
| Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders |
10 |
| Gadolinium-Based Contrast Agent-Related Toxicities |
9 |
| Treatment Strategies for Dravet Syndrome |
9 |
| Metformin for Weight Gain Associated with Second-Generation Antipsychotics in Children and Adolescents: A Systematic Review and Meta-Analysis |
9 |
| Tardive Dyskinesia Associated with Atypical Antipsychotics: Prevalence, Mechanisms and Management Strategies |
9 |
| Recent Advances in Pharmacotherapy for Episodic Migraine |
9 |
| Impact of Glatiramer Acetate on B Cell-Mediated Pathogenesis of Multiple Sclerosis |
8 |
| MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study |
8 |
| Social Skills Deficits in Autism Spectrum Disorder: Potential Biological Origins and Progress in Developing Therapeutic Agents |
8 |
| Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential |
8 |
| Long-Term Neuropsychological Outcomes from an Open-Label Phase I/IIa Trial of 2-Hydroxypropyl-beta-Cyclodextrins (VTS-270) in Niemann-Pick Disease, Type C1 |
8 |
| Effects of Clozapine on the Gut: Cross-Sectional Study of Delayed Gastric Emptying and Small and Large Intestinal Dysmotility |
8 |
| Fatigue in Patients with Major Depressive Disorder: Prevalence, Burden and Pharmacological Approaches to Management |
8 |
| Targeting Mitochondria in Alzheimer Disease: Rationale and Perspectives |
8 |
| The Safety of Second-Generation Antipsychotics During Pregnancy: A Clinically Focused Review |
7 |
| Risk of Intracranial Hemorrhage Associated with the Use of Antidepressants Inhibiting Serotonin Reuptake: A Systematic Review |
7 |
| Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents |
7 |
| An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials |
7 |
| Recent Advances in the Drug Treatment of Dravet Syndrome |
7 |
| Assessment and Management of Neuropsychiatric Symptoms in Parkinson's Disease |
7 |
| Cannabinoid-Based Therapies and Brain Development: Potential Harmful Effect of Early Modulation of the Endocannabinoid System |
7 |
| An Update on Vitamin D and Disease Activity in Multiple Sclerosis |
7 |
| Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development |
7 |
| Novel Treatment Opportunities Against Cognitive Impairment in Parkinson's Disease with an Emphasis on Diabetes-Related Pathways |
7 |
